These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 8157945

  • 21. Cell membrane cation transport systems during aldosterone antagonism.
    Lijnen P, Petrov V.
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):462-8. PubMed ID: 8847860
    [Abstract] [Full Text] [Related]

  • 22. [Treatment of primary hypercholesterolemia with pravastatin. A placebo-controlled trial].
    Frederiksen SM, Larsen ML, Oxenbøll IB, Pindborg T, Haghfelt T.
    Ugeskr Laeger; 1993 Sep 06; 155(36):2794-9. PubMed ID: 8236548
    [Abstract] [Full Text] [Related]

  • 23. Cellular and humoral effects of naftopidil in man.
    Lijnen P.
    Methods Find Exp Clin Pharmacol; 1992 Apr 06; 14(3):211-7. PubMed ID: 1352563
    [Abstract] [Full Text] [Related]

  • 24. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
    Koter M, Broncel M, Chojnowska-Jezierska J, Klikczynska K, Franiak I.
    Eur J Clin Pharmacol; 2002 Nov 06; 58(8):501-6. PubMed ID: 12451426
    [Abstract] [Full Text] [Related]

  • 25. Relationships between membrane lipids and ion transport in red blood cells of Dahl rats.
    Vokurková M, Nováková O, Dobesová Z, Kunes J, Zicha J.
    Life Sci; 2005 Aug 12; 77(13):1452-64. PubMed ID: 15936778
    [Abstract] [Full Text] [Related]

  • 26. Erythrocyte cation transport systems and membrane lipids in insulin-dependent diabetes.
    Lijnen P, Fenyvesi A, Bex M, Bouillon R, Amery A.
    Am J Hypertens; 1993 Sep 12; 6(9):763-70. PubMed ID: 8110430
    [Abstract] [Full Text] [Related]

  • 27. [Modulation of Na+,K+-pump activity and Na+,Li+-exchange in rabbit erythrocytes at various stages of cholesterol feeding].
    Makarov VL.
    Biokhimiia; 1995 Sep 12; 60(9):1468-76. PubMed ID: 8562655
    [Abstract] [Full Text] [Related]

  • 28. Changes in erythrocyte sodium and plasma lipids associated with physical training.
    Hespel P, Lijnen P, Fagard R, M'Buyamba-Kabangu JR, Van Hoof R, Lissens W, Rosseneu M, Amery A.
    J Hypertens; 1988 Feb 12; 6(2):159-66. PubMed ID: 2450911
    [Abstract] [Full Text] [Related]

  • 29. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect.
    Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT, Badimon JJ, Ambrose JA.
    Thromb Haemost; 2000 May 12; 83(5):688-92. PubMed ID: 10823263
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women.
    Peverill RE, Smolich JJ, Malan E, Goldstat R, Davis SR.
    Maturitas; 2006 Jan 20; 53(2):158-65. PubMed ID: 16368469
    [Abstract] [Full Text] [Related]

  • 32. Relationship of red blood cell ion transport alterations and serum lipid abnormalities in Lyon genetically hypertensive rats.
    Zicha J, Dobesová Z, Kunes J, Vincent M.
    Can J Physiol Pharmacol; 1997 Sep 20; 75(9):1123-8. PubMed ID: 9365824
    [Abstract] [Full Text] [Related]

  • 33. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin.
    Le Quan Sang KH, Levenson J, Megnien JL, Simon A, Devynck MA.
    Arterioscler Thromb Vasc Biol; 1995 Jun 20; 15(6):759-64. PubMed ID: 7773730
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 20; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience.
    Beigel Y, Brook G, Eisenberg S, Fainaru M, Harats D, Levy Y, Rubinstein A, Skurnik Y.
    Isr J Med Sci; 1993 May 20; 29(5):272-7. PubMed ID: 8314685
    [Abstract] [Full Text] [Related]

  • 37. Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment.
    Takeshita M, Katsuragi Y, Kusuhara M, Higashi K, Miyajima E, Mizuno K, Mori K, Obata T, Ohmori R, Ohsuzu F, Onodera Y, Sano J, Sawada S, Tabata S, Tokimitsu I, Tomonobu K, Yamashita T, Yasukawa T, Yonemura A, Nakamura H.
    Nutr Metab Cardiovasc Dis; 2008 Sep 20; 18(7):483-91. PubMed ID: 17964767
    [Abstract] [Full Text] [Related]

  • 38. Blood pressure and cationic transport systems during combined calcium channel blocker and calcium administration in males.
    Lijnen P, Petrov V.
    Methods Find Exp Clin Pharmacol; 1996 May 20; 18(4):287-94. PubMed ID: 8803961
    [Abstract] [Full Text] [Related]

  • 39. [Transmembrane Na+ transport kinetics in arterial hypertension: relations with vascular risk parameters].
    Caballero Oliver A, Stiefel García-Junco P, García-Donas López MA, Villar Ortiz J, Carneado de la Fuente J.
    Med Clin (Barc); 1995 Dec 08; 105(20):768-73. PubMed ID: 8558976
    [Abstract] [Full Text] [Related]

  • 40. [Influence of pravastatin therapy on expression of P-selectin].
    Yin S, Ma L, Xu L.
    Zhonghua Xue Ye Xue Za Zhi; 1998 Sep 08; 19(9):461-3. PubMed ID: 11189483
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.